This rat study investigated ketamine (2.5 mg/kg) interactions with gut-microbiota in rats to understand its antidepressant and anti-inflammatory properties. The data concluded that there are some antidepressant and anti-inflammatory effects of ketamine treatment through its interaction with specific gut bacteria such as Lactobacillus, Turicibacter, and Sarcina and confirmed the usefulness of microbiome as a target for therapy using ketamine for some of its anti-inflammatory effects for specific inflammatory diseases including Irritable bowel syndrome (IBS). The study called for more detailed investigations of the interaction of microbiome with central mediators of mood and/or inflammatory disorders.
Background
Appreciable evidence suggest that dysbiosis in microbiota, reflected in gut microbial imbalance plays a key role in the pathogenesis of neuropsychiatric disorders including depression and inflammatory diseases. Recently, the antidepressant properties of ketamine have gained prominence due to its fast and long lasting effects. Additional uses for ketamine in inflammatory disorders such as irritable bowel syndrome have been suggested. However, ketamine’s exact mechanism of action and potential effects on microbiome is not known. Here, we examined the effects of low dose ketamine, known to induce antidepressant effects, on stool microbiome profile in adult male Wistar rats. Animals (5/group) were injected intraperitoneally with ketamine (2.5 mg/kg) or saline, daily for 7 days and sacrificed on day 8 when intestinal stools were collected and stored at − 80 °C. DNA was extracted from the samples and the 16 S rRNA gene-based microbiota analysis was performed using 16S Metagenomics application.
Results
At genus-level, ketamine strikingly amplified Lactobacillus, Turicibacter and Sarcina by 3.3, 26 and 42 fold, respectively. Conversely, opportunistic pathogens Mucispirillum and Ruminococcus were reduced by approximately 2.6 and 26 fold, respectively, in ketamine group. Low levels of Lactobacillus and Turicibacter are associated with various disorders including depression and administration of certain species of Lactobacillus ameliorates depressive-like behavior in animal models. Hence, some of the antidepressant effects of ketamine might be mediated through its interaction with these gut bacteria. Additionally, high level of Ruminococcus is positively associated with the severity of irritable bowel syndrome (IBS), and some species of Mucispirillum have been associated with intestinal inflammation. Indirect evidence of anti-inflammatory role of Sarcina has been documented. Hence, some of the anti-inflammatory effects of ketamine and its usefulness in specific inflammatory diseases including IBS may be mediated through its interaction with these latter bacteria.
Conclusion
Our data suggest that at least some of the antidepressant and anti-inflammatory effects of daily ketamine treatment for 7 days may be mediated via its interaction with specific gut bacteria. These findings further validate the usefulness of microbiome as a target for therapeutic intervention and call for more detailed investigation of microbiome interaction with central mediators of mood and/or inflammatory disorders.
Papers in Blossom that reference this study
Wilkowska, A., Szałach, L., Cubała, W. J. · Neuropsychiatric Disease And Treatment (2020)
Hashimoto, K. · Psychiatry and Clinical Neurosciences (2019)
Getachew and colleagues situate this study within growing evidence that the gut microbiota and the brain communicate bidirectionally and that disturbances in gut microbial communities (dysbiosis) are implicated in depression and inflammatory disorders. The authors note clinical and preclinical findings linking gastrointestinal conditions, altered immune signalling (for example elevated IL-1β, IL-6 and TNFα) and depressive symptoms, as well as data showing that manipulating the microbiome (probiotics, antibiotics, fecal transfer) can change behaviour and biomarkers such as tryptophan metabolism and brain BDNF. Against this background, ketamine has emerged as a fast-acting antidepressant and has been proposed for some inflammatory conditions, but its interactions with the gut microbiome, particularly after repeated dosing, are not well characterised. This study therefore aimed to determine whether chronic low-dose ketamine alters the composition of the colonic microbiota in adult male Wistar rats, with particular attention to taxa previously implicated in mood regulation or inflammatory processes. The principal hypothesis was that ketamine would enrich microbiota associated with mood elevation and suppress taxa linked to inflammation. The work is positioned as an exploratory, hypothesis-driven examination of microbiome changes after seven daily intraperitoneal injections of ketamine at a dose previously shown to produce antidepressant-like effects in this model.
Adult male Wistar rats, approximately three months old, were used. Animals were acclimated for at least one week, housed 2–3 per cage, and randomly allocated to either a ketamine or saline control group (n = 5 per group). To minimise cross-contamination, treatment groups were housed separately. Ketamine (KETAHESIA® diluted to 2.5 mg/ml) or saline was administered intraperitoneally at 2.5 mg/kg, 1 ml/kg volume, once daily for seven consecutive days. Animals were sacrificed 24 hours after the last injection (day 8) and colons containing stools were rapidly frozen and stored at −80 °C. Total DNA was extracted from approximately 200 mg stool using a commercial stool DNA isolation kit with bead homogenisation and spin-column purification; DNA quality and quantity were assessed by spectrophotometry. The V3–V4 hypervariable region of the 16S rRNA gene was PCR-amplified from 12.5 ng of DNA and libraries were prepared following the Illumina MiSeq 16S metagenomic protocol. Paired-end sequencing was performed at 2 × 300 bp on an Illumina MiSeq. Bioinformatic taxonomic classification used the Illumina 16S metagenomics pipeline and an Illumina-curated version of the GreenGenes taxonomic database (extracted text shows 'GeenGenes'). Diversity and richness were estimated with the Shannon Diversity Index and mean species counts; an operational abundance cutoff of 0.01% was applied to define 'qualified' species. Between-group comparisons used Student’s t-test assuming equal variance, with a two-tailed significance threshold of p < 0.05. For analyses at the family and genus levels the samples from each group were pooled, producing only two aggregate samples (control versus treated); in these pooled comparisons no statistical test was performed and the investigators applied a conservative minimum 1.5-fold change threshold to flag potentially important differences.
Sequencing detected 1121 species across both groups, with fewer than 700 species passing the 0.01% abundance cutoff (630 in saline, 670 in ketamine; P = 0.22). Overall diversity measured by the Shannon Diversity Index did not differ between groups (saline 2.62 vs ketamine 2.60, P = 0.99). The authors report identification of 29 phyla, 56 classes, 106 orders, 234 families, and 600 genera across samples, and state there were no differences in percent reads across taxa at a broad level. At the phylum level, ketamine significantly reduced the abundances of Deferribacteres and Tenericutes, with reported reductions of approximately 22-fold and 2-fold, respectively, compared with saline. Class-level decreases mirrored phylum findings: Deferribacteres and Mollicutes decreased by about 22-fold and 2-fold, respectively. At the order level, ketamine increased Turicibacterales abundance by 28-fold and decreased Desulfuromonadales, Deferribacterales, Thermoanaerobacterales (extracted text spelling varied) and Anaeroplasmatales by approximately 2.2-, 20-, 2- and 3.4-fold, respectively. Because family- and genus-level analyses were performed on pooled group samples (preventing inferential statistics), the authors report fold changes and used a 1.5-fold cutoff to indicate notable differences. At the family level, ketamine reportedly enriched Turicibacteraceae (98-fold), Clostridiaceae (89-fold) and Lactobacillaceae (1.5-fold), while reducing Ruminococcaceae and Deferribacteraceae by approximately 2.3-fold and 26-fold, respectively. At the genus level, ketamine increased Sarcina, Turicibacter and Lactobacillus by 42-, 20- and 2-fold, respectively, and decreased Mucispirillum and Ruminococcus by about 26.3- and 2.3-fold, respectively. These genus-level changes are highlighted as the most striking effects reported after seven days of 2.5 mg/kg i.p. ketamine.
The researchers interpret their results as demonstrating marked shifts in gut microbial ecology following chronic low-dose ketamine, with fold changes ranging from about 2- to 42-fold in specific taxa. They emphasise increases in Lactobacillus and Turicibacter and reductions in Mucispirillum and Ruminococcus, proposing that these directional changes may relate to ketamine's antidepressant and anti-inflammatory properties. Lactobacillus and Turicibacter are noted as taxa that have low abundance in some disorders including depression, and prior animal work showing that administration of Lactobacillus can ameliorate depressive-like behaviour is offered as supporting evidence for a microbiome-mediated contribution to ketamine's effects. The authors also connect elevated Ruminococcus and Mucispirillum with inflammatory states such as irritable bowel syndrome and colitis; accordingly, ketamine-associated reductions in these taxa are suggested as a potential mechanism for its anti-inflammatory activity. Sarcina is discussed as a low-abundance genus whose large increase after ketamine might also be anti-inflammatory. Mechanistic ideas raised include modulation of butyrate-producing (butyrogenic) bacteria and resultant effects on host energy metabolism, anti-inflammatory signalling, and histone deacetylase (HDAC) inhibition, which can influence gene expression. Changes in mucin-degrading taxa such as Mucispirillum are also discussed in relation to gut barrier integrity ('leaky gut'), lipopolysaccharide (LPS) translocation and systemic inflammation, all of which are linked in the literature to mood and gastrointestinal disease. The authors situate their findings alongside previous studies, including a report that acute (R)-ketamine attenuated stress-associated increases in Ruminococcaceae and reversed behavioural deficits, and suggest that ketamine-induced microbiome changes could help restore gut equilibrium disrupted by diet, stress or inflammation. They acknowledge the need for further characterisation of specific microbial species, functional analyses to link taxa changes with central and peripheral mediators (for example cytokines and BDNF), and examination of potential sex differences. The extracted text indicates that family- and genus-level analyses were performed on pooled samples and therefore lacked formal statistical testing; the investigators used fold-change thresholds to highlight differences, and they call for more detailed follow-up work to establish causality and functional consequences.
The authors conclude that seven days of low-dose ketamine in male Wistar rats produced significant increases in several low-abundance, potentially probiotic genera (Lactobacillus, Turicibacter and Sarcina) and marked decreases in opportunistic or inflammation-associated taxa (Ruminococcus and Mucispirillum). They propose that these divergent shifts — increases in genera thought to be beneficial and decreases in putative pathogens — may, at least in part, contribute to ketamine's sustained antidepressant and anti-inflammatory effects. Finally, the paper calls for further functional studies of individual bacterial species and their interactions with central and peripheral mediators of affect and inflammation, and for consideration of possible sex differences in future work.
Converging evidence suggests that the brain and the gut microbiota are in bidirectional communication with each other and also with inflammatory processes. Thus, on the one hand, dysbiosis, an imbalance in the microbiota community, may occur in depression and chronic stress due to altered brain signaling to the gut. On the other hand, altered gut microbial signaling to the brain may result in brain alterations. Clinical evidence supporting gut microbiota-brain-inflammatory processes interaction, specifically in relation to mood dysregulation such as in major depressive disorder (MDD) include: 1. depressive symptoms are often co-morbid with gastrointestinal (GI) disorders such as metabolic syndrome, inflammatory bowel disease, and irritable bowel syndrome (IBS); 2. this comorbidity presents increased risk for disease progression and poorer outcome, and treatment of one condition can reverse the risk for the other; 3. some classes of antibiotics have been shown to have antidepressant effects. Conversely, some antidepressants may also possess antimicrobial properties. Moreover, germ-free animals show increased depressive-like behavior that can be reversed by administering a single bacterium such as Bifidobacterium infantis. Similarly, significant depletion of the gut microbiota with selective antibiotics can result in depressive-like phenotype. Fecal microbiota transplantation from depressed patients to microbiota-depleted rats induces behavioral and physiological characteristic of depression (i.e., anhedonia and altered tryptophan metabolism) in these rats. Conversely, probiotics consumption can increase plasma levels of tryptophan and reduce levels of the pro-inflammatory cytokines such as interleukin-1-beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα). Interestingly, reduction of these pro-inflammatory cytokines can result in abatement of depressive-like behavior. Overall, these data suggest involvement of microbiome in pathogenesis of depressive behavior and possibly the effectiveness of antidepressants. Off-label use of ketamine for depression is becoming prominent due to its prompt and sustained antidepressant effects. Indeed, (S)-ketamine (esketamine) is in approval process by FDA as a fast-acting antidepressant with particular application in treatment-resistant depression and suicidal ideation. The purported effects of acute ketamine include inhibition of NMDA (N-methyl-d-aspartate) receptors and activation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors as well as molecular signaling of mTOR (the mammalian target of rapamycin), which result in enhancement of hippocampal brain-derived neurotrophic factor (BDNF) and increased synaptogenesis. The sustained effectiveness of acute ketamine is likely mediated by additional mechanisms as increased BDNF levels are not maintained beyond 24 h after ketamine administration. In this regard, interaction of acute ketamine with gut microbiota has recently been reported. Moreover, it was demonstrated that gut microbiome is capable of modulating central BDNF. However, to our knowledge no study has examined the effects of chronic ketamine on gut microbiota. In addition to its well established antidepressant effects, ketamine has also been advocated for use in inflammatory diseases such as ulcerative colitis. However, here also, no studies on interaction between ketamine and gut microbiota implicated in inflammatory diseases has been carried out. Thus, this study was conducted to determine the effects of chronic ketamine on gut microbiota, especially those implicated in mood regulation and/or inflammatory responses. Our hypothesis was that ketamine would promote microbiota implicated in mood elevation and suppress microbiota implicated in inflammatory diseases.
Age matched, approximately 3 months old adult male Wistar rats (Evigo, USA) were housed 2-3 per cage in standard polypropylene shoebox cages (42 × 20.5 × 20 cm) on hardwood chip bedding (alpha-dry) in a designated room. Throughout the experiment, animals had access to food (Harlan Tek Lab) and water ad libitum. The room was maintained at 24-26 °C at 51-66% relative humidity, on a 12-h light/dark cycle (lights on at 7 am). In order to acclimate the subjects to the housing conditions, animals arrived at least one week prior to initiation of any experiment. During this period, they were gentled once daily in order to minimize any stress effects that might result from routine handling.
A ready-made preparation KETAHESIA® inj. Sol. purchased from Henry Schein (Dublin, OH) (100 mg/ml), was diluted with saline to obtain desired concentration of 2.5 mg/ml.
Following one week of acclimation, the animals were randomly divided into two groups, control and experimental (n = 5 each) and were housed in separate cages. Animals belonging to the same group were also randomly selected and housed together (2-3 animals/cage). This housing method assured that the animals in both groups were exposed to identical environment and that there would not be any cross-contaminatin between the treated vs the control group. The number of animals used in each group was based on behavioral observations seen using similar number of animals. Control group was injected daily (around noon) with saline, whereas the experimental group received ketamine (2.5 mg/kg). All injections were done intraperitoneally (i.p.) and were carried out for 7 consecutive days. The volume of injection was 1 ml/kg. The low dose of ketamine used in this study was based on our previous study, where clearly an antidepressant effect of such a dose and duration was observed
On day 8, approximately 24 h after the last ketamine or saline injection, the animals were sacrificed by decapitation, alternating between the groups as described previously. Colons containing stools were collected, quick-frozen on dry ice and stored at -80 °C. This method of rapid-freezing is considered best-practice for preserving stool DNA samples.
Total DNA was isolated from stool samples using Norgen's Stool DNA Isolation Kit and the Precellys Dual-24 Homogenizer (Bertin Technologies). Purification was based on spin column chromatography using resin as the separation matrix. Briefly, 200 mg stool samples were bead-homogenized after adding 1 mL of Lysis Buffer L. One hundred μL of lysis additive was added and vortexed, followed by centrifugation at 20,000 x g for 5 min. The clear supernatant was transferred (600 μL) to a DNAase-free microcetrifuge tube. Next, the samples were centrifuged and 100 μL of Binding Buffer I was added to the clean supernatant and incubated on ice for 10 min. Equal amounts of 70% ethanol were then added to the clean supernatant from Binding Buffer I lysate after centrifugation. The protocol was then followed for complete DNA isolation. The purified DNA was quantified and analyzed for purity using the NanoDrop™ 2000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). Twenty μL of purified DNA was then quick-frozen on dry ice and shipped to Norgen Biotek (Thorold, ON, Canada) for 16S rRNA gene analysis.
Briefly, the V3-V4 hypervariable region of the bacterial 16S rRNA gene was amplified from 12.5 ng of stool DNA. The amplicons were then cleaned, sequenced according to the Illumina MiSeq 16S Metagenomic Sequencing Library Preparation protocol. The final library was paired-end sequenced at 2 × 300 bp using a MiSeq Reagent Kit v3 on the Illumina MiSeq platform. For bioinformatic analysis, the sequencing data was analyzed using the Illumina 16S metagenomics app (Illumina 16S Metagenimics Pippeline (v1.0.1), which performs taxonomic classification of 16S rRNA targeted amplicons using an Illumina-curated version of the GeenGenes taxonomic database. The app provides interactive visualization and raw classification output for per-sample and aggregate analyses. Classification was performed using the Illumina 16 S Metagenomics workflow, which is also available in the MiSeq Reporter software. The algorithm uses a high-performance implementation of the Ribosomal Database Project (RDP) Classifier described in.
Since comparison was performed between two groups with equal variance (ketamine-and saline-treated animals), Student T-test was applied for detecting significant differences in specific measured parameters. The cut-off for statistical significance was p < 0.05, two-tailed
Figuredepicts the effects of chronic low dose ketamine on gut bacterial diversity (A) and richness (B). A total of 1121 different bacterial species were identified in both saline and ketamine groups. Overall, there was no significant difference in either diversity (Fig.) as estimated by the Shannon Diversity Index (SDI) (saline control vs. ketamine; 2.62 vs. 2.60, P = 0.99) or species richness (Fig.) as measured by mean species number. Although a total of 1121species were identified, only less than 700 (saline control vs. ketamine; 630 vs. 670, P = 0.22) were considered qualified (i.e., made the cut off at 0.01% abundance).
There were a total number of 29 Phyla, 56 classes, 106 orders, 234 families, 600 genera and 1121 species identified in the two groups. There were no differences between the saline and ketamine group in percent reads, i.e., percentage of identified sequences belonging to each taxon (Fig.).
Ketamine significantly reduced abundances of two phyla, Deferibacteres and Tenericutes (Fig.). Overall there were 29 different phyla identified in the two groups. Deferibacteres and Tenericutes are low-abundance phyla accounting for less than 2% of the total phyla reads. Ketamine selectively reduced Deferibacteres and Tenericutes by approximately 22 and 2 fold, respectively, compared to saline control group.
Ketamine significantly reduced the levels of two classes, Deferrribacteres and Mollicutes by 22 and 2 fold, respectively, compared to the saline group (Fig.). There were a total of 56 different classes identified between the two groups.
Ketamine significantly increased the abundance of Turicibacterales order by 28 fold, and reduced the abundance of four orders: Desulfuromonadales, Deferribacterales, Theromonaerobacterales and Anaeroplasmatales by 2.2, 20, 2 and 3.4 fold, respectively, compared to saline control group (Fig.). There were a total of 106 different classes identified in both groups.
Ketamine significantly enriched Tuberibacteraceae by 98 fold, Clostridiaceae by 89 fold and Lactobacillaceae by1.5 fold, whereas Deferrribacteraceae and Ruminococcaceae were reduced by approximately 26 and 2.3 fold, respectively, compared to the saline control group at the family-level (Fig.). There were a total of 234 different families. It should be noted that for analysis at the family level, the samples were pooled and hence overall there were two gorups to be compared (control vs treated). Since a statistical analysis could not be perforemed in such cases, we used a conservative cutoff point of a minimum of 1.5 fold difference between the gorups, which could imply important changes.
Ketamine significantly enriched abundances of genera Sarcina, Turicibater, Lactobacillus by 42, 20 and 2 fold respectively, Whereas, levels of Mucispirillum and Ruminococcaceae were decreased by 26.3 and 2.3 fold, respectively, compared to saline control group (Fig.).Effects of 7 day ketamine (2.5 mg/kg i.p.) on gut bacterial distribution of taxa. Values are percent total reads/taxa/group (n = 5). There were no significant differences in the % reads in taxon between saline and ketamine group. Note: the samples from each group were pooled and hence overall there were two groups to be compared (control vs treated) There were a total of 600 different genera. It should be noted that for analysis at the genus level, the samples were pooled and hence overall there were two gorups to be compared (control vs treated). Since a statistical analysis could not be perforemed in such cases, we used a conservative cutoff point of a minimum of 1.5 fold difference between the gorups, which could imply important changes.
Our data indicates drastic effects of chronic low dose ketamine on gut microbial ecology, ranging from 2 to 42 fold changes in specific genera. For example, Lactobacillus and Turicibacter were increased by approximately 2 and 20 fold, respectively, whereas Mucispirillum and Ruminococcus were reduced by approximately 26 and 2.3 fold, respectively. Since low levels of Lactobacillus and Turicibacter are associated with various disorders including depression, it might be suggested that these gut microbiomes may play a role in ketamine's antidepressant properties. Further support for this contention is provided by findings that administration of Lactobacillus ameliorates depressive-like behavior in animal models. As mentioned earlier, antidepressant effects of low dose ketamine have been amply supported in both preclinical as well as clinical studies. Conversely, elevated levels of Mucispirillum and Ruminococcus are associated with inflammatory processes. Indeed, high levels of Ruminococcus has been shown to be positively associated with the severity of irritable bowel disease and some species of Mucispirillum may cause intestinal inflammation. Hence, reduction of these microorganisms by ketamine, may suggest an additional novel mechanism for ketamine's anti-inflammatory effects. On the other hand, since low levels of Sarcina has been implicated in inflammatory processes, its 42-fold magnification by ketamine may also be a contributory factor to ketamine's anti-inflammatory properties. Here also, as noted earlier, 3 fold, respectively. Note: the samples from each group were pooled and hence overall there were two groups to be compared (control vs treated) Fig.Effects of 7 day ketamine (2.5 mg/kg i.p.) on fold change in abundance of gut bacterial class. Values are the fold change over saline control group mean (n = 5). Ketamine significantly decreased Deferribacteres and Mollicutes compared to saline group by 22 and 2 fold, respectively. Note: the samples from each group were pooled and hence overall there were two groups to be compared (control vs treated) anti-inflammatory effects of ketamine are well documented. In addition, changes in low-abundance groups such as Lactobaccilus, Sarcina and Turicibacter can markedly influence the gut ecosystem. For example, these groups contain species that can degrade complex polysaccharides to short chain fatty acids such as butyrate. Changes in these "butyrogenic" bacteria may in turn influence metabolic, inflammatory bowel or neurological/neuropsychiatric disorders. Indeed, butyrate, which can be used as a source of energy by the host, confers many benefits including anti-inflammatory effects. Butyrate can also inhibit histone deacetylase (HDAC), resulting in increased levels of histone acetylation, thereby affecting gene expression. Curiously, modest antidepressant-like effects of sodium butyrate, a weak and highly non-specific inhibitor of class I and class II HDACs, have been reported. Furthermore, by lowering colonic pH, butyrate may confer an added for probiotic microbiota such as Turicibacter, which thrive in lower pH. Curiously, Westernized diet implicated in many disorders including metabolic syndrome, is linked to lower levels of Lactobacillus and Sarcina, but higher levels of Ruminococcus. Mucispirillum is a gram-negative anaerobic bacterium that can Fig.Effects of day ketamine (2.5 mg/kg i.p.) on fold change in abundance of gut bacterial order. Values are the fold change over saline control group mean (n = 5). Ketamine significantly increased Turicibacterales by 28 fold and decreased Desulfuromonadales, Deferribacterales, Theromonaerobacterales and Anaeroplasmatales by 2.2 and 3.4 fold, respectively, compared to saline group. There were a total of 106 different orders. Numbers on the columns refer to the fold-change. Note: the samples from each group were pooled and hence overall there were two groups to be compared (control vs treated) Fig.Effects of 7 day ketamine (2.5 mg/kg i.p.) on percent abundance of gut bacterial family. Values are mean % abundance of group mean (n = 5). Ketamine significantly enriched abundance of genera Lactobacillaceae, Turicibateraceae, Clostridiaceae by 1.5, 98 and 89 fold respectively. Conversely, ketamine reduced abundance of Ruminococcaceae and Deferribacteraceae by 2.3 and 26.3 folds respectively compared to saline group. * indicate significant changes compared to saline. There were a total of 234 families constantly generate lipopolysaccharide (LPS) as an integral component of its outer cell membrane. This and other opportunistic bacteria flourish in gut environment causing inflammation and dysbiosis. To this effect, an association between an increase in Ruminococcus level and diverticulitis, total hip arthroplasty, IBS severity and exercise-induced stress have been reported. Interestingly, exercise-related stress may have similar effects on microbiome. Thus, it was shown that forced exercise reduces levels of Turicibacter, and increases cecal Ruminococcus leading to intestinal inflammation, whereas voluntary wheel running for 6 weeks attenuates symptoms in a colitis mouse model. A recent study by Qu et al.indicates that acute (R)-ketamine significantly attenuated the increased levels of Ruminococcaceae (a family-taxa of Ruminococcus), in susceptible mice after chronic social defeat. Ketamine's lowering of Ruminococcaceae and reversal of the behavioral deficits, including depressive-like behavior induced by social defeat, suggest that Ruminococcaceae may play a role in stress-induced depressive behavior. Our results also suggest that antidepressant effects of chronic ketamine might be mediated through reduction of Ruminococcus in the gut. On the other hand, ketamine's elevation of gut genera Lactobacillus, Sarcina and Turicibacter reported here, suggests that reestablishment of gut equilibrium by chronic ketamine might be a contributory factor to its anti-inflammatory effects. This contention is further strengthened by findings that ameliorative effects of Turicibacter are correlated with increased intestinal butyric acid. Thus, taken together, it might be suggested that chronic ketamine can ameliorate dysbiotic brought about by diet, stressful exercise or inflammation via its interaction with gut microbiome genera such as Lactobacillus, Sarcina and Turicibacter. It is also of relevance to note that gut bacteria can influence the colonic mucus layer (mucin), a physical barrier that separates trillions of gut bacteria from the host. Some microbiota such as Mucispirillum, can increase gut penetrability leading to 'leaky gut' and reduce growth rate of the inner mucus layer. Indeed, Mucispirillum, has a potential capacity to degrade mucin by actively destroying the microenvironment of the gut, leading to leaky gut, which is considered a key contributor to the co-morbid condition of depression and intestinal disorders. Moreover, Mucispirillum is positively associated with increases in plasma level of LPS, intestinal inflammation and severity of IBS. Mucispirillum is also considered colitogenic and is used as a microbial marker in active colitis. Thus, some of the anti-inflammatory and possibly the antidepressant effects of ketamine might also be mediated through reduction of Mucispirillum and gut permeability. In this regard, future characterization of the relationship between Mucispirillum and affect is warranted. Elucidation of the direct microbiome influence on neurobiological substrates of mood and on peripheral and central mediators of inflammatory processes may provide novel therapeutic targets in these disorders. It is noteworthy that many animal studies support the notion that central changes in cytokines and BDNF, both of which are directly linked to affective behavior, are influenced by gut microbiota. For example, oral administration of some antimicrobials to mice results in transient alteration of microbiota, increased hippocampal BDNF and antidepressant-like behavior. However, i.p. administration of antimicrobials to mice or oral administration of antimicrobials to germ-free mice do not affect behavior, suggesting that changes in gut microbiomes are necessary to affect central BDNF levels and/or behavior. Thus, inducing changes in the gut microbiota using probiotics, prebiotics or antimicrobial drugs are novel and promising targets in countering affective disorders. In addition, as suggested earlier, manipulation of gut microbiome may also be a novel approach in combatting inflammatory disorders including colitis. Therefore, further investigation of the role of specific microbiomes in inflammatory processes and interaction of effective anti-inflammatory compounds with this system can not only enhance our understanding of the gut-brain axis, but can also lead to novel intervention in inflammatory diseases.
Overall, our findings indicate that chronic administration of ketamine results in significant increases in the levels of low-abundance bacteria genera (e.g. Lactobacillus, Turicibacter and Sarcina), and significant decreases in opportunistic pathogens (e.g. Ruminococcus and Mucispirallum) in male Wistar rats. Thus, it may be suggested that divergent changes in colonic microbiota, where there are increases in probiotic and decreases in pathogenic genera, may in part contribute to the sustained antidepressant and anti-inflammatory effects of ketamine. Clearly, further detailed functional analysis of the role of individual bacterial species and their interactions with central and peripheral mediators of affective behavior or inflammatory processes is warranted. In this vein possible gender effects should also be taken into consideration.
Create a free account to open full-text PDFs.